COMMUNIQUÉS West-GlobeNewswire
-
LB Pharmaceuticals Appoints Kaya Pai Panandiker as Chief Commercial Officer
12/11/2025 -
Beacon Therapeutics to Participate in the Jefferies Global Healthcare Conference
12/11/2025 -
Picard to Attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum November 20, 2025, in New York City
12/11/2025 -
Evaxion announce 2026 financial calendar
12/11/2025 -
Mainz Biomed Showcases Innovative Cancer Detection Solutions at MEDICA 2025
12/11/2025 -
Standard Dental Labs Inc.: Investor Education Series — Part 2
12/11/2025 -
X9, Inc. Announces Successful Completion of First-in-Human Feasibility Study for Ultrasound-Guided, Power-Assisted Needle Insertion Device in Hemodialysis Cannulation
12/11/2025 -
FDA Clears Magstim Magnetic Stimulation for Chronic Pain Treatment
12/11/2025 -
Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders
12/11/2025 -
Radiopharm Theranostics starts enrollment of the Third Cohort of Phase 1 Dose Escalation Clinical Trial of 177Lu-RAD204
12/11/2025 -
Jushi Holdings Inc. Announces Grand Opening of Beyond Hello™ Little Ferry in New Jersey
12/11/2025 -
Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical Update
12/11/2025 -
Solana Company Announces Intent to Tokenize HSDT Shares on Superstate’s Opening Bell
12/11/2025 -
Indaptus Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
12/11/2025 -
Profound Medical Announces Strategic Distribution Agreement with Getz Healthcare to Bring TULSA-PRO® to Australia and New Zealand
12/11/2025 -
IO Biotech Announces Participation in Upcoming Investor Conferences
12/11/2025 -
Chiesi Group Enters into an Exclusive License Agreement with Aliada Therapeutics, a Wholly Owned Subsidiary of AbbVie, to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders
12/11/2025 -
Intelligent Bio Solutions Reports Fiscal 2026 First Quarter Financial Results and Operational Highlights, Delivering Record Revenue Growth
12/11/2025 -
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2025 Financial Results on November 17, 2025
12/11/2025
Pages